Daily Sepsis Research Analysis
Three complementary advances in sepsis research stand out today: metabolic reprogramming via fasting-induced ketogenesis (acetoacetate) markedly potentiates antibiotic efficacy and survival in murine sepsis; a necroptosis-related gene panel identified in patients shows diagnostic and prognostic promise; and combining neuron-specific enolase with cerebral oximetry variability improves detection and risk stratification of sepsis-associated encephalopathy.
Summary
Three complementary advances in sepsis research stand out today: metabolic reprogramming via fasting-induced ketogenesis (acetoacetate) markedly potentiates antibiotic efficacy and survival in murine sepsis; a necroptosis-related gene panel identified in patients shows diagnostic and prognostic promise; and combining neuron-specific enolase with cerebral oximetry variability improves detection and risk stratification of sepsis-associated encephalopathy.
Research Themes
- Metabolic adjuncts to enhance antibiotic efficacy in sepsis
- Cell death pathways (necroptosis) as diagnostic/prognostic targets
- Bedside neuromonitoring and biomarkers for sepsis-associated encephalopathy
Selected Articles
1. Fasting-induced ketogenesis sensitizes bacteria to antibiotic treatment.
In multiple murine sepsis models, fasting-induced ketogenesis markedly enhanced antibiotic efficacy, boosting bacterial clearance and survival. Mechanistically, the ketone body acetoacetate increased bacterial membrane permeability, depleted positively charged amino acids and putrescine, and amplified antibiotic lethality.
Impact: Reveals a previously unrecognized metabolic lever—ketogenesis—to sensitize pathogens to antibiotics and improve survival, opening a translational avenue for adjunctive sepsis therapy.
Clinical Implications: Suggests potential adjunct strategies: short-term metabolic modulation (e.g., ketone body supplementation) to enhance antibiotic killing in bacterial sepsis. Human safety, dosing, and patient selection require rigorous clinical trials.
Key Findings
- Fasting potentiated antibiotic treatment in murine sepsis due to Salmonella Typhimurium, Klebsiella pneumoniae, and Enterobacter cloacae, improving bacterial clearance and survival.
- Fasting-induced ketogenesis, specifically acetoacetate, increased outer and inner bacterial membrane permeability and antibiotic lethality.
- Acetoacetate depleted bacterial positively charged amino acids and putrescine, causing membrane malfunctions and redox-related lethality; antibiotic–ketone body combination therapy recapitulated fasting benefits.
Methodological Strengths
- Robust in vivo validation across multiple Gram-negative sepsis models with survival endpoints.
- Mechanistic dissection linking acetoacetate to membrane permeability changes, amino acid depletion, and enhanced antibiotic lethality.
Limitations
- Preclinical mouse and bacterial models; no human clinical data.
- Safety and feasibility of fasting or ketone body supplementation in acutely ill septic patients remain untested.
Future Directions: Phase I/II trials to evaluate safety and pharmacodynamics of ketone body supplementation with antibiotics; patient stratification by pathogen and metabolic status; exploration of optimal dosing and timing.
Fasting metabolism is a commonly observed motivational response to acute infections and is conceptualized as being beneficial for host survival. Here, we show that fasting potentiates antibiotic treatment for murine sepsis caused by Salmonella Typhimurium, Klebsiella pneumoniae, and Enterobacter cloacae, resulting in increased bacterial clearance and improved host immune responses and survival. This effect is mediated by fasting-induced ketogenesis and could be alternatively implemented by combination therapy with antibiotics and ketone bodies. We show that the ketone body acetoacetate is an effector that sensitizes bacteria to antibiotic treatment by increasing antibiotic lethality and outer and inner membrane permeability. Our results demonstrate that acetoacetate depletes bacterial amino acids, particularly positively charged amino acids and putrescine, leading to cell membrane malfunctions and redox-related lethality. This study reveals an unrecognized role of ketogenesis in antibiotic treatment and a potential ketone body-based treatment strategy for bacterial sepsis.
2. Identification and Verification of Necroptosis-Related Genes in Patients With Sepsis by Bioinformatic Analysis and Molecular Experiments.
Eight necroptosis-related DEGs (PYGL, TNF, CYLD, FADD, TLR3 up; TP53, FASLG, NLRP6 down) were identified in sepsis and validated via qPCR/ELISA and cell-based assays. Corresponding proteins showed strong ROC performance for diagnosing sepsis and predicting in-hospital mortality, implicating necroptosis as a clinically relevant pathway.
Impact: Bridges bioinformatics with wet-lab validation to deliver a tractable biomarker panel and mechanistic pointer (necroptosis) for sepsis diagnosis and risk stratification.
Clinical Implications: Supports development of a necroptosis-focused biomarker panel for early sepsis recognition and mortality risk prediction; may guide future trials of necroptosis-modulating therapies.
Key Findings
- Identified eight necroptosis-related differentially expressed genes: upregulated (PYGL, TNF, CYLD, FADD, TLR3) and downregulated (TP53, FASLG, NLRP6) in sepsis versus healthy controls.
- Protein levels corresponding to these DEGs achieved excellent or considerable accuracy for sepsis diagnosis and in-hospital mortality prediction (ROC analyses).
- Cell assays with plasma transfection and caspase-8 inhibition supported necroptosis involvement, aligning protein changes with DEG directionality.
Methodological Strengths
- Integrated bioinformatic discovery with multi-step experimental validation (qPCR, ELISA, Western blot, cytokine array).
- Diagnostic and prognostic evaluation using ROC analyses enhances translational relevance.
Limitations
- Unequal group sizes (n=133 sepsis vs n=12 controls) and lack of external validation cohort.
- Plasma transfection cell models may not fully recapitulate in vivo pathophysiology; causal inference is limited.
Future Directions: Prospective multicenter validation of the biomarker panel, assay standardization, and interventional studies targeting necroptosis pathways.
Although necroptosis is an emerging mechanism of multiple organ dysfunction in sepsis, data on the mechanistic link between necroptosis and sepsis are scarce. Bioinformatic analysis was performed to compare the gene profiles between the sepsis (n = 133) and healthy control (n = 12) groups and identify necroptosis-related differentially expressed genes (DEGs). The identified necroptosis-related DEGs were verified by three-step molecular experiments: (1) quantitative real-time PCR and enzyme-linked immunosorbent assay; (2) cell culture, transfection and Western blotting; and (3) cytokine array with apoptosis inhibition. Additionally, receiver-operating characteristic curve analyses were performed to evaluate the performance of the corresponding proteins to the necroptosis-related DEGs in diagnosing sepsis and in predicting in-hospital mortality of patients with sepsis. Eight necroptosis-related DEGs, including five upregulated (PYGL, TNF, CYLD, FADD and TLR3) and three downregulated (TP53, FASLG and NLRP6) DEGs, were identified. Moreover, the levels of the corresponding proteins to necroptosis-related DEGs showed excellent or considerable accuracy in diagnosing sepsis and in predicting the mortality of sepsis patients. In cell culture media transfected with plasma from the sepsis and control groups, Western blotting revealed that the levels of the corresponding proteins were increased in the upregulated DEGs and decreased in the downregulated DEGs. The cytokine array revealed cytokines in cell culture media transfected with plasma from patients with sepsis while preventing apoptosis by inhibiting the caspase-8 activity, wherein the transfected cells potentially underwent necroptosis. Eight necroptosis-related DEGs were identified in patients with sepsis by bioinformatic analysis and verified by molecular experiments, implying that necroptosis may be a key mechanism of sepsis.
3. Combined cerebral oxygen saturation and neuron-specific enolase evaluation for diagnosis and prognosis of sepsis-associated encephalopathy.
In a prospective cohort of 70 septic patients, both NSE and cerebral rSO2% independently discriminated SAE, and their combination improved diagnostic AUC to 0.749. Higher NSE and rSO2% were associated with significantly lower 28-day survival, supporting their use for risk stratification.
Impact: Provides a pragmatic, bedside-applicable biomarker and neuromonitoring combination to improve detection and prognostication of SAE.
Clinical Implications: Combining serum NSE with cerebral oximetry variability could aid early SAE detection and 28-day risk stratification, informing targeted neuroprotective strategies and monitoring intensity.
Key Findings
- NSE and rSO2% were independent indicators of SAE in a prospective cohort (P < 0.05).
- Combined NSE and rSO2% achieved an AUC of 0.749 for SAE diagnosis, outperforming single markers.
- Elevated NSE and increased rSO2% were associated with significantly reduced 28-day survival (P < 0.001).
Methodological Strengths
- Prospective observational design with prespecified biomarkers and 28-day outcomes.
- Use of combined biomarker and neuromonitoring parameter with ROC and survival analyses.
Limitations
- Single-center study with a modest sample size (n=70) and limited external generalizability.
- Moderate diagnostic performance (AUC 0.749); thresholds and management algorithms not defined.
Future Directions: Multicenter validation, standardization of rSO2% measurement, and integration into clinical decision pathways to test impact on neurological outcomes.
Sepsis-associated encephalopathy (SAE) represents a severe neurological complication in sepsis, characterized by high mortality and cognitive impairment. Although clinical significance, SAE lacks effective diagnostic and prognostic tools. This study evaluates the predictive value of neuron-specific enolase (NSE) and regional cerebral oxygen saturation variability (rSO₂%) as indicators for diagnosing and prognosing SAE. A prospective observational study enrolled 70 sepsis patients, classified into SAE and non-SAE groups. Serum NSE levels and rSO₂% were measured alongside clinical data and 28-day mortality outcomes. NSE and rSO₂% were identified as independent indicators of SAE (P < 0.05). Combined analysis achieved a higher diagnostic accuracy, with an area under the ROC curve of 0.749, compared to single indicators. Kaplan-Meier survival analysis reveals that elevated NSE levels and increased rSO₂% are associated with significantly reduced 28-day survival (P < 0.001). These findings suggest that NSE and rSO₂%are valuable indicators for the diagnosis and prognosticating SAE. Their combined application significantly improves diagnostic efficacy, providing a basis for personalized early intervention strategies.